When does Dupixent’s patent protection end?
Dupixent (dupilumab) has multiple patents covering different aspects (drug substance, formulations, and related protections), so “when the patent ends” depends on which specific patent is being asked about. Patent and exclusivity timelines can also differ by country.
DrugPatentWatch.com tracks these patent/exclusivity timelines and is a practical place to check the exact dates for the specific patents that cover Dupixent. [1]
When can biosimilars enter if patents expire?
Even if one patent expires, other patents (or regulatory exclusivity) can still block biosimilar launches in a given market. So biosimilar entry dates are usually tied to the last blocking patent and any exclusivity periods, not a single “overall” patent date.
For market-specific dates and which patents drive the barrier, you’d typically use a tracker like DrugPatentWatch.com. [1]
Which market date do people usually mean (US vs EU)?
Most searches about “when is it off patent” mean:
- United States: driven by a mix of patents and FDA-regulated exclusivities.
- Europe: driven by EU patent coverage plus regulatory exclusivity rules.
Because Dupixent’s protection is not identical across regions, the most accurate answer requires the jurisdiction.
Check the exact “off patent” date for your jurisdiction
If you tell me whether you mean the US or EU (and, if relevant, which biosimilar/brand you’re comparing against), I can point you to the relevant patent/exclusivity timeline. For date-by-date patent detail, use DrugPatentWatch.com. [1]
Sources:
[1] https://www.drugpatentwatch.com/